Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000043700 | SCV000071713 | likely benign | Cystic fibrosis | 2023-04-26 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000727142 | SCV000601073 | uncertain significance | not provided | 2023-08-04 | criteria provided, single submitter | clinical testing | In the published literature, this variant has been reported in individuals with cystic fibrosis (PMIDs: 31665830 (2020), 18832460 (2008), 11168023 (2001), 10204861 (1999)). Functional studies indicate this variant may impact promoter activity but not at a significant difference from the wild type (PMIDs: 17678620 (2007), 21948798 (2012)). The frequency of this variant in the general population, 0.014 (117/8656 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Based on the available information, we are unable to determine the clinical significance of this variant. |
Eurofins Ntd Llc |
RCV000727142 | SCV000706119 | uncertain significance | not provided | 2018-06-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000727142 | SCV001810789 | uncertain significance | not provided | 2024-04-11 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate decreased Sp1 and USF DNA-binding and decreased transcriptional activity in one study that utilized a core promoter construct, but the associated transcriptional activity was not significantly different from wild type in a second study that utilized a full-length promoter construct (PMID: 17678620, 21948798); Identified in individuals with cystic fibrosis in published literature, but in whom a second CFTR variant was either not detected or not specified (PMID: 10204861, 31665830, 18832460); Describes a nucleotide substitution 226 basepairs upstream of the ATG translational start site in the 5' untranslated region (UTR); Also known as c.-94G>T; This variant is associated with the following publications: (PMID: 12939925, 26656651, 11168023, 31665830, 18832460, 21948798, 10204861, 37313453, 17678620) |
Ambry Genetics | RCV000043700 | SCV002736623 | benign | Cystic fibrosis | 2015-08-12 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Revvity Omics, |
RCV000727142 | SCV003831632 | uncertain significance | not provided | 2021-12-02 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000727142 | SCV004565191 | likely benign | not provided | 2023-11-15 | criteria provided, single submitter | clinical testing |